Patents by Inventor Robert Purcell
Robert Purcell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240082380Abstract: The present invention provides methods for enhancing the efficacy and/or safety of a vaccine. In certain embodiments, the invention provides methods to increase or potentiate the immune response to a vaccine in a subject in need thereof. The methods of the present invention comprise administering to a subject in need thereof an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody in combination with said vaccine. In certain embodiments, the methods of the present invention are used to afford enhanced protection to an infectious disease such as whooping cough.Type: ApplicationFiled: July 5, 2023Publication date: March 14, 2024Inventors: Lisa Purcell, Neil Graham, Andrew J. Murphy, Robert Evans
-
Publication number: 20240075659Abstract: Moldable material comprising at least 5% by weight of polymeric regrind material recovered from Automotive Shredder Residue (ASR) and method of manufacturing the same are provided. The method comprises the steps of providing a polymer material sorted from ASR; grinding the polymer material sorted from ASR to form a regrind material; depositing the regrind material into a liquid solution having a specific gravity and performing a liquid density separation; removing a plurality of pieces of regrind material having a specific gravity of less than the liquid solution specific gravity from a surface of the liquid; conditioning the removed pieces of regrind material; blending the respective pieces of regrind material with a primary polymer to create a polymeric blend; compounding the polymeric blend via the addition of at least one additive thereby creating a plastics compound; and supplying the resultant plastics compound to an extrusion machine to produce the moldable material.Type: ApplicationFiled: September 6, 2023Publication date: March 7, 2024Applicant: Louis Padnos Iron and Metal CompanyInventors: Gary Barnett, Erik Jepsen, Lisa Purcell, Martin Przekadziniski, Robert Herweyer, Jason Bergsma
-
Patent number: 11918200Abstract: Meniscal extrusion can occur due detachment of the knee capsule from structures of the knee. Disclosed herein are methods to repair the meniscal detachment. Additionally, cadaveric and synthetic models can be used to teach said methods of repair.Type: GrantFiled: June 3, 2021Date of Patent: March 5, 2024Assignee: Arthrex, Inc.Inventors: David Crane, George Paletta, John Purcell, Andrew Osika, Robert Harrison
-
Patent number: 10100346Abstract: The present invention relates to molecular approaches to the production of nucleic acid sequences, which comprises the genome of infectious hepatitis C virus. In particular, the invention provides nucleic acid sequences which comprise the genomes of infectious hepatitis C viruses of either genotype 3a (strain S52) or genotype 4a (strain ED43). The invention therefore relates to the use of the nucleic acid sequences and polypeptides encoded by all or part of the sequences in the development of vaccines and diagnostic assays for HCV and in the development of screening assays for the identification of antiviral agents for HCV. The invention therefore also relates to the use of viral particles derived from laboratory animals infected with S52 and ED43 viruses.Type: GrantFiled: April 28, 2017Date of Patent: October 16, 2018Assignees: Hvidovre Hospital, The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Judith M. Gottwein, Troels Kasper Hoyer Scheel, Robert Purcell, Jens Bukh
-
Publication number: 20170240950Abstract: The present invention relates to molecular approaches to the production of nucleic acid sequences, which comprises the genome of infectious hepatitis C virus. In particular, the invention provides nucleic acid sequences which comprise the genomes of infectious hepatitis C viruses of either genotype 3a (strain S52) or genotype 4a (strain ED43). The invention therefore relates to the use of the nucleic acid sequences and polypeptides encoded by all or part of the sequences in the development of vaccines and diagnostic assays for HCV and in the development of screening assays for the identification of antiviral agents for HCV. The invention therefore also relates to the use of viral particles derived from laboratory animals infected with S52 and ED43 viruses.Type: ApplicationFiled: April 28, 2017Publication date: August 24, 2017Inventors: Judith M. Gottwein, Troels Kasper Hoyer Scheel, Robert Purcell, Jens Bukh
-
Patent number: 9683269Abstract: The present invention relates to molecular approaches to the production of nucleic acid sequences, which comprises the genome of infectious hepatitis C virus. In particular, the invention provides nucleic acid sequences which comprise the genomes of infectious hepatitis C viruses of either genotype 3a (strain S52) or genotype 4a (strain ED43). The invention therefore relates to the use of the nucleic acid sequences and polypeptides encoded by all or part of the sequences in the development of vaccines and diagnostic assays for HCV and in the development of screening assays for the identification of antiviral agents for HCV. The invention therefore also relates to the use of viral particles derived from laboratory animals infected with S52 and ED43 viruses.Type: GrantFiled: October 14, 2014Date of Patent: June 20, 2017Assignees: Hvidovre Hospital, The United States of America, As Represented by the Secretary, Department of Health and Human ServicesInventors: Judith M. Gottwein, Troels Kasper Hoyer Scheel, Robert Purcell, Jens Bukh
-
Publication number: 20150105290Abstract: The present invention relates to molecular approaches to the production of nucleic acid sequences, which comprises the genome of infectious hepatitis C virus. In particular, the invention provides nucleic acid sequences which comprise the genomes of infectious hepatitis C viruses of either genotype 3a (strain S52) or genotype 4a (strain ED43). The invention therefore relates to the use of the nucleic acid sequences and polypeptides encoded by all or part of the sequences in the development of vaccines and diagnostic assays for HCV and in the development of screening assays for the identification of antiviral agents for HCV. The invention therefore also relates to the use of viral particles derived from laboratory animals infected with S52 and ED43 viruses.Type: ApplicationFiled: October 14, 2014Publication date: April 16, 2015Inventors: Judith M. Gottwein, Troels Kasper Hoyer Scheel, Robert Purcell, Jens Bukh
-
Patent number: 8946398Abstract: The present invention relates to molecular approaches to the production of nucleic acid sequences, which comprises the genome of infectious hepatitis C virus. In particular, invention provides nucleic acid sequences which comprise the genomes of infectious hepatitis C viruses of either genotype 3a (strain S52) or genotype 4a (strain ED43). The invention therefore relates to the use of the nucleic acid sequences and polypeptides encoded by all or part of the sequences in the development of vaccines and diagnostic assays for HCV and in the development of screening assays for the identification of antiviral agents for HCV. The invention therefore also relates to the use of viral particles derived from laboratory animals infected with S52 and ED43 viruses.Type: GrantFiled: September 16, 2010Date of Patent: February 3, 2015Assignees: Hvidovre Hospital, The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Judith M. Gottwein, Troels Kasper Hoyer Scheel, Robert Purcell, Jens Bukh
-
Publication number: 20120189648Abstract: The present invention relates to molecular approaches to the production of nucleic acid sequences, which comprises the genome of infectious hepatitis C virus. In particular, invention provides nucleic acid sequences which comprise the genomes of infectious hepatitis C viruses of either genotype 3a (strain S52) or genotype 4a (strain ED43). The invention therefore relates to the use of the nucleic acid sequences and polypeptides encoded by all or part of the sequences in the development of vaccines and diagnostic assays for HCV and in the development of screening assays for the identification of antiviral agents for HCV. The invention therefore also relates to the use of viral particles derived from laboratory animals infected with S52 and ED43 viruses.Type: ApplicationFiled: September 16, 2010Publication date: July 26, 2012Applicant: HVIDOVRE HOSPITALInventors: Judith M. Gottwein, Troels Kasper Hoyer Scheel, Robert Purcell, Jens Bukh
-
Patent number: 7635476Abstract: Chimpanzee monoclonal antibodies and antigen binding fragments including a ?1-chain CDR3 region that bind hepatitis A virus (HAV) antigen are disclosed herein. The antibodies neutralize HAV. Also disclosed are methods for using these antibodies and antigen binding fragments in the detection of hepatitis A virus, the inhibition of infection of a subject with hepatitis A virus, and in screening for agents that affect HAV.Type: GrantFiled: April 23, 2007Date of Patent: December 22, 2009Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Darren J. Schofield, Suzanne U. Emerson, Robert Purcell, II
-
Publication number: 20090311248Abstract: The invention relates to anti-HCV antibodies and more specifically to neutralizing anti-HCV antibodies and their variable and complementarity determining regions (CDR). In particular, the neutralizing anti-HCV antibodies are neutralizing anti-HCV envelope protein 1 (HCV E1) antibodies. Also subject of the invention are compositions comprising these antibodies, CDRs or variable regions, and compounds comprising at least one of the CDRs or variable regions of said antibodies. Further subject of the invention are the application of any of said antibodies, CDRs, variable regions or compounds in HCV prophylaxis, therapy, and diagnosis, as well as methods for producing the antibodies.Type: ApplicationFiled: March 22, 2007Publication date: December 17, 2009Inventors: Erik Depla, Robert Purcell, Jens Bukh, Suzanne Emerson, Jean-Christophe Meunier
-
Publication number: 20090104207Abstract: The invention relates to anti-HCV antibodies and more specifically to neutralizing anti-HCV antibodies and their variable and complementarity determining regions (CDR). In particular, the neutralizing anti-HCV antibodies are neutralizing anti-HCV envelope protein 1 (HCV E1) antibodies. Also subject of the invention are compositions comprising these antibodies, CDRs or variable regions, and compounds comprising at least one of the CDRs or variable regions of said antibodies. Further subject of the invention are the application of any of said antibodies, CDRs, variable regions or compounds in HCV prophylaxis, therapy, and diagnosis, as well as methods for producing the antibodies.Type: ApplicationFiled: March 22, 2007Publication date: April 23, 2009Inventors: Erik Depla, Robert Purcell, Jens Bukh, Suzanne Emerson, Jens-Christophe Meunier
-
Publication number: 20080014212Abstract: The present invention discloses nucleic acid sequences which encode infectious hepatitis C viruses and the use of these sequences, and polypeptides encoded by all or part of these sequences, in the development of vaccines and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV.Type: ApplicationFiled: April 9, 2007Publication date: January 17, 2008Inventors: Masayuki Yanagi, Jens Bukh, Suzanne Emerson, Robert Purcell
-
Publication number: 20070287667Abstract: Chimpanzee monoclonal antibodies and antigen binding fragments including a ?1-chain CDR3 region that bind hepatitis A virus (HAV) antigen are disclosed herein. The antibodies neutralize HAV. Also disclosed are methods for using these antibodies and antigen binding fragments in the detection of hepatitis A virus, the inhibition of infection of a subject with hepatitis A virus, and in screening for agents that affect HAV.Type: ApplicationFiled: April 23, 2007Publication date: December 13, 2007Inventors: Darren Schofield, Suzanne Emerson, Robert Purcell
-
Publication number: 20070141668Abstract: The present invention discloses nucleic acid sequence which encodes infectious hepatitis C virus of strain HC-J6CH, genotype 2a, and the use of the sequence, and polypeptides encoded by all or part of the sequence, in the development of vaccines and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV.Type: ApplicationFiled: June 12, 2006Publication date: June 21, 2007Inventors: Masayuki Yanagi, Jens Bukh, Suzanne Emerson, Robert Purcell
-
Publication number: 20070134256Abstract: The present invention relates to monoclonal antibodies that bind or neutralize dengue type 1, 2, 3, and/or 4 virus. The invention provides such antibodies, fragments of such antibodies retaining dengue virus-binding ability, fully human or humanized antibodies retaining dengue virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: ApplicationFiled: December 3, 2004Publication date: June 14, 2007Inventors: Ching-Juh Lai, Robert Purcell
-
Publication number: 20050233316Abstract: The invention describes the identification of a major neutralization site of hepatitis E virus (HEV) and the use of this neutralization site in methods of vaccination and in methods of screening for neutralizing antibodies to HEV. The invention also describes the isolation and characterization of neutralizing chimpanzee monoclonal antibodies reactive to the neutralization site and the use of these antibodies in the diagnosis, treatment and prevention of HEV.Type: ApplicationFiled: February 9, 2005Publication date: October 20, 2005Inventors: Darren Schofield, Suzanne Emerson, Robert Purcell